TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21755811

Group type: EXPERIMENTAL
Intervention: Test formulation (dorzolamide 20 mg/ml + timolol 5 mg/ml eye drops)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Reference formulation (dorzolamide 20 mg/ml + timolol 5 mg/ml eye drops)
Number of subjects: 38
Study: 19851157

Group type: EXPERIMENTAL
Intervention: High-intensity TENS (2 Hz, 250 mu) applied for 30 minutes
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Low-intensity TENS (2 Hz, 250 mu) applied for 30 minutes
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo TENS applied for 30 minutes
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no TENS applied)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: All TENS groups (high-intensity, low-intensity, placebo)
Number of subjects: 40
Study: 16430342

Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg BID
Number of subjects: 237

Group type: COMPARATOR
Intervention: Routine care (gabapentin, amitriptyline, venlafaxine)
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg BID and Routine care
Number of subjects: 237
Study: 15291206

Group type: EXPERIMENTAL
Intervention: Right handers performing a constrained criterion movement with the right arm
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Left handers performing a constrained criterion movement with the left arm
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Right handers and left handers
Number of subjects: 30
Study: 11406858

Group type: EXPERIMENTAL
Intervention: Procyanidin B-2 (1% tonic)
Number of subjects: 29
Study: 8708952

Group type: EXPERIMENTAL
Intervention: bioresorbable membranes
Number of subjects: 36

Group type: COMPARATOR
Intervention: non-resorbable (ePTFE) barrier membranes
Number of subjects: 36

Group type: COMPARATOR
Intervention: access flap procedure (MWF)
Number of subjects: 36
Study: 1907087

Group type: EXPERIMENTAL
Intervention: Coronary bypass surgery
Number of subjects: 303

Group type: COMPARATOR
Intervention: Intravenous thrombolytic therapy
Number of subjects: 303
Study: 6311392

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy with cyclophosphamide (1.5 g/m2 days 1‐3), 4‐dimethyl epipodophylloxtin (200 mg/m2 days 1‐3), vincristine (1.5 mg/m2 days 1 and 3), and Adriamycin (80 mg/m2 day 1)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy without Adriamycin
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Prophylactic brain irradiation (3000 rad) and 4 courses of usual doses of the same drugs
Number of subjects: 14
Study: 30872550

Group type: EXPERIMENTAL
Intervention: Home-based video education + behaviour contract plus usual care
Number of subjects: 200

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 200
Study: 28498636

Group type: EXPERIMENTAL
Intervention: Preoperative bowel stimulation via the distal limb of the loop ileostomy using an 18Fr Foley catheter and infusing with 500 ml of normal saline mixed with 30 g of a thickening agent (Nestle© Thicken‐Up©), performed 10 times over 3 weeks before ileostomy closure.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional care (control group not explicitly defined in the abstract).
Number of subjects: 0
Study: 26452060

Group type: EXPERIMENTAL
Intervention: PIK3CA mutations detected by Sanger/qPCR
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: PIK3CA mutations detected by NGS
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: Lobular histology, low tumor grade, and luminal A tumors
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: Luminal B tumors
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: Overall incidence of PIK3CA mutations
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: Presence and type of PIK3CA mutations
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: PIK3CA mutation status and PTEN low protein expression
Number of subjects: 1008
Study: 22951284

Group type: EXPERIMENTAL
Intervention: Resistance strength training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lifting a light load under uncertainty
Number of subjects: 0
Study: 21252171

Group type: EXPERIMENTAL
Intervention: Prasugrel 60 mg loading dose (LD)/10 mg maintenance dose (MD)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Clopidogrel 600 mg LD/150 mg MD
Number of subjects: 35
Study: 19339838

Group type: EXPERIMENTAL
Intervention: Fondaparinux 1.5 mg once daily
Number of subjects: 353
Study: 17432637

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) at Taiyang (EX-HN 5)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Oral administration of western medicine
Number of subjects: 300
Study: 15851115

Group type: EXPERIMENTAL
Intervention: Anatomical approach (group I)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Voltage-guided approach (group II)
Number of subjects: 32
Study: 11558009

Group type: EXPERIMENTAL
Intervention: Intercostal Nerve Block (ICB) with Bupivacaine (BUP) 3 mg/kg 0.5 % with epinephrine 1 : 200 000
Number of subjects: 20

Group type: COMPARATOR
Intervention: Meperidine 1 mg/kg administered i.v.
Number of subjects: 20
Study: 9626638

Group type: EXPERIMENTAL
Intervention: PTH (400 IU/day subcutaneous human PTH (1-34)) + alendronate (10 mg/day)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Alendronate (10 mg/day) alone
Number of subjects: 10
Study: 7840332

Group type: EXPERIMENTAL
Intervention: Older men (aged 60-75 years)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Younger men (aged 20-30 years)
Number of subjects: 2
Study: 2646848

Group type: EXPERIMENTAL
Intervention: Intravenous bupivacaine 0.5% 20 ml with adrenaline (5 micrograms/ml) administered through an indwelling intrapleural catheter at 4-hour intervals four times daily for 2 days.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intramuscular oxycodone on request (control group).
Number of subjects: 0
Study: 1101615

Group type: EXPERIMENTAL
Intervention: etidocaine 1% with adrenaline 5 mug/ml
Number of subjects: 40

Group type: COMPARATOR
Intervention: bupivacaine 0.5% with adrenaline 5 mug/ml
Number of subjects: 40
Study: 31315649

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 28100527

Group type: EXPERIMENTAL
Intervention: THRIVE with jaw support and age-specific flow rates
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control with jaw support during apnoea
Number of subjects: 48
Study: 26434745

Group type: EXPERIMENTAL
Intervention: One-stage surgical protocol (Group I)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Two-stage surgical protocol (Group II)
Number of subjects: 16
Study: 23341738

Group type: EXPERIMENTAL
Intervention: multicomponent training
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: progressive resistance training
Number of subjects: 42
Study: 22180711

Group type: EXPERIMENTAL
Intervention: PEG + Asc (low-volume plus ascorbic acid)
Number of subjects: 144

Group type: COMPARATOR
Intervention: PEG + Sim (high-volume plus simethicone)
Number of subjects: 144
Study: 19426557

Group type: EXPERIMENTAL
Intervention: Interactive website designed to empower claimants, consisting of five interactive modules and additional resources.
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Interactive website designed to empower claimants.
Number of subjects: 230

Group type: COMPARATOR
Intervention: Control group directed to a website with commonly available information only.
Number of subjects: 230
Study: 17019993

Group type: EXPERIMENTAL
Intervention: Diffractive lens SA60D3
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Monofocal lens MA60BM
Number of subjects: 29

Group type: COMPARATOR
Intervention: Healthy control (clear own lens)
Number of subjects: 29
Study: 15333165

Group type: EXPERIMENTAL
Intervention: Glucose (high-glucose drink)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Fanta Orange (intermediate-GI drink)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Apple & Cherry Juice (low-GI drink)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 10
Study: 10773182

Group type: EXPERIMENTAL
Intervention: Antidepressant agents
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9483814

Group type: EXPERIMENTAL
Intervention: Paracervical anaesthesia (2 x 10 ml 0.5% Bupivacain solution)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Only Pethidin intravenously and Butylscopolamine rectally
Number of subjects: 20
Study: 8416441

Group type: EXPERIMENTAL
Intervention: Zoladex (goserelin 3.6 mg) implant every 4 weeks plus estradiol valerate, 2 mg/day, with norethisterone 5 mg from days 22-28
Number of subjects: 60

Group type: COMPARATOR
Intervention: Zoladex (goserelin 3.6 mg) implant every 4 weeks plus placebo ERT tablets daily
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo implant every 4 weeks plus placebo ERT tablets daily
Number of subjects: 60
Study: 3792432

Group type: EXPERIMENTAL
Intervention: Intravenous administration of 10 mg ketanserin
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Intramuscular administration of 10 mg ketanserin
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Oral administration of 20 mg ketanserin
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Oral administration of 40 mg ketanserin
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Oral administration of 60 mg ketanserin
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ketanserin-ol (metabolite)
Number of subjects: 10
Study: 30176891

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 102

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 102
Study: 27471203

Group type: EXPERIMENTAL
Intervention: Oral salbutamol
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Inhaled salbutamol
Number of subjects: 10
Study: 25158551

Group type: EXPERIMENTAL
Intervention: SWL at 80 shots per minute (group A)
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: SWL at 60 shots per minute (group B)
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: SWL at 45 shots per minute (group C)
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: SWL at 30 shots per minute (group D)
Number of subjects: 247
Study: 22677347

Group type: EXPERIMENTAL
Intervention: Video‐assisted thoracoscopic surgery (VATS)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Thoracotomy
Number of subjects: 37
Study: 20018575

Group type: EXPERIMENTAL
Intervention: Amantadine 200mg
Number of subjects: 297

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 297
Study: 18782439

Group type: EXPERIMENTAL
Intervention: 0.8 mg sCT with 50 ml of water
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: 0.8 mg sCT with 50 ml of water taken 30 and 60 minutes prior to meal time
Number of subjects: 56

Group type: COMPARATOR
Intervention: nasal calcitonin
Number of subjects: 56
Study: 15940460

Group type: EXPERIMENTAL
Intervention: 70 mg erythromycin
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: 200 mg erythromycin
Number of subjects: 35

Group type: COMPARATOR
Intervention: Saline placebo (0.9%)
Number of subjects: 35
Study: 11819022

Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 58

Group type: COMPARATOR
Intervention: Nonsurgical treatment
Number of subjects: 58
Study: 10071275

Group type: EXPERIMENTAL
Intervention: Pamidronate (90 mg, 2-hour intravenous infusion every 4 weeks for 24 cycles)
Number of subjects: 372

Group type: COMPARATOR
Intervention: Placebo (2-hour intravenous infusion every 4 weeks for 24 cycles)
Number of subjects: 372
Study: 7564371

Group type: EXPERIMENTAL
Intervention: Diltiazem CD (once-daily controlled-delivery)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Diltiazem SR (twice-daily sustained-release)
Number of subjects: 35
Study: 2208927

Group type: EXPERIMENTAL
Intervention: Ioversol (Optiray Mallinckrodt Inc.)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Iohexol (Omnipaque, Nycomed [UK] Ltd)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both Ioversol and Iohexol
Number of subjects: 80
Study: 550366

Group type: EXPERIMENTAL
Intervention: Softened water
Number of subjects: 28

Group type: COMPARATOR
Intervention: De-ionized water
Number of subjects: 28
Study: 31863149

Group type: EXPERIMENTAL
Intervention: Dietary program
Number of subjects: 152

Group type: COMPARATOR
Intervention: No diet
Number of subjects: 152
Study: 31008950

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 349

Group type: COMPARATOR
Intervention: Sham electroacupuncture (SA)
Number of subjects: 349

Group type: EXPERIMENTAL
Intervention: Both EA and SA
Number of subjects: 349
Study: 28540844

Group type: EXPERIMENTAL
Intervention: Fp MDPI 200 μg
Number of subjects: 674

Group type: EXPERIMENTAL
Intervention: FS MDPI 200/12.5 μg
Number of subjects: 674

Group type: COMPARATOR
Intervention: Fp HFA 440 μg
Number of subjects: 674

Group type: COMPARATOR
Intervention: FS DPI 500/50 μg
Number of subjects: 674

Group type: COMPARATOR
Intervention: All Fp MDPI doses
Number of subjects: 674

Group type: COMPARATOR
Intervention: All FS MDPI doses
Number of subjects: 674

Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 674
Study: 25839338

Group type: EXPERIMENTAL
Intervention: Shakuyaku-Kanzo-to (7.5 g/d)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Biperiden (3 mg/d)
Number of subjects: 22
Study: 24004620

Group type: EXPERIMENTAL
Intervention: Prolonged use of aspirin before tooth extraction (observation group I)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Prolonged use of aspirin before tooth extraction (observation group II)
Number of subjects: 300

Group type: COMPARATOR
Intervention: No aspirin before tooth extraction (control group I)
Number of subjects: 300

Group type: COMPARATOR
Intervention: No aspirin before tooth extraction (control group II)
Number of subjects: 300
Study: 21871072

Group type: EXPERIMENTAL
Intervention: Standardized small bites technique
Number of subjects: 576

Group type: COMPARATOR
Intervention: Standardized large bites technique
Number of subjects: 576
Study: 19796561

Group type: EXPERIMENTAL
Intervention: Tailored rehabilitation program including hand and face specific rehabilitation, global rehabilitation techniques (hydrokinesytherapy or land-based program), respiratory exercises, and hand lymphatic drainage when necessary.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Tailored rehabilitation program (same as above)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Educational advice and medical information about SSc (observational group)
Number of subjects: 20
Study: 18076441

Group type: EXPERIMENTAL
Intervention: Nasal valsalva
Number of subjects: 26

Group type: COMPARATOR
Intervention: Trumpet manoeuvre
Number of subjects: 26
Study: 15347767

Group type: EXPERIMENTAL
Intervention: Fermented infant formula (FIF)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard formula (placebo)
Number of subjects: 30
Study: 12577329

Group type: EXPERIMENTAL
Intervention: Huangqi Zengmian Powder (HQZMP)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group (non-HQZMP treated)
Number of subjects: 37
Study: 9875910

Group type: EXPERIMENTAL
Intervention: CVVH (continuous venovenous hemofiltration)
Number of subjects: 13

Group type: COMPARATOR
Intervention: CVVHD (continuous venovenous hemodialysis)
Number of subjects: 13

Group type: COMPARATOR
Intervention: CVVHD
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: CVVH
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: CVVH and CVVHD
Number of subjects: 13
Study: 7986770

Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Fluphenazine
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 2915556

Group type: EXPERIMENTAL
Intervention: Fresh whole blood
Number of subjects: 24

Group type: COMPARATOR
Intervention: Platelet concentrates (8 units)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Platelet concentrates (10 units)
Number of subjects: 24
Study: 5082545

Group type: EXPERIMENTAL
Intervention: Metolazone (doses ranging from 20-150 mg)
Number of subjects: 14
Study: 29098425

Group type: EXPERIMENTAL
Intervention: SFA-enriched breakfast
Number of subjects: 18

Group type: COMPARATOR
Intervention: unSFA and fiber-enriched breakfast
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: SFA-enriched meal test
Number of subjects: 18

Group type: COMPARATOR
Intervention: unSFA meal
Number of subjects: 18
Study: 27757552

Group type: EXPERIMENTAL
Intervention: Fingolimod 0.5 mg
Number of subjects: 906
Study: 26334629

Group type: EXPERIMENTAL
Intervention: In-person motivational interviewing (MI) plus usual care (UC)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Web-based motivational interviewing (web-MI) plus usual care (UC)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Usual care (UC) only
Number of subjects: 159
Study: 23469947

Group type: EXPERIMENTAL
Intervention: Plasma Zn, vitamin B12, and a-tocopherol
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Plasma g-tocopherol
Number of subjects: 285
Study: 21510895

Group type: EXPERIMENTAL
Intervention: Methylphenidate (0.5 mg/kg in divided b.i.d. dose)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 157
Study: 18339033

Group type: EXPERIMENTAL
Intervention: ELISA (Hitazyme Chlamydophila pneumoniae)
Number of subjects: 100

Group type: COMPARATOR
Intervention: MIF test or immunoblot
Number of subjects: 100
Study: 15798460

Group type: EXPERIMENTAL
Intervention: Beger procedure
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Frey procedure
Number of subjects: 74
Study: 12640250

Group type: EXPERIMENTAL
Intervention: Caffeine (250 mg)
Number of subjects: 20
Study: 10378563

Group type: EXPERIMENTAL
Intervention: Heated humidifier (Fisher & Paykel; Auckland, New Zealand)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Hygrobac‐Dar (Mallinckrodt, Mirandola, Italy)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Visual evaluation of condensation in the flex‐tube
Number of subjects: 45
Study: 8635258

Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 4444

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4444
Study: 1506150

Group type: EXPERIMENTAL
Intervention: 0.10 mmol/kg gadoteridol
Number of subjects: 411
Study: 6389142

Group type: EXPERIMENTAL
Intervention: Chronic antidysrhythmic treatment (specific agents not mentioned)
Number of subjects: 568

Group type: COMPARATOR
Intervention: Control (not specified, but implied to be no treatment or placebo)
Number of subjects: 568

Group type: EXPERIMENTAL
Intervention: Chronic antidysrhythmic treatment
Number of subjects: 568

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 568
Study: 31481144

Group type: EXPERIMENTAL
Intervention: Holmium laser enucleation of the prostate (HoLEP)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 80
Study: 29970142

Group type: EXPERIMENTAL
Intervention: Whole-body vibration strength-training for 6 weeks
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo intervention for 6 weeks
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Whole-body vibration strength-training
Number of subjects: 82
Study: 26597179

Group type: EXPERIMENTAL
Intervention: Edoxaban 60 mg daily for 3 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Switching from Rivaroxaban 20 mg daily to Edoxaban 60 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Switching from Dabigatran Etexilate 150 mg twice daily to Edoxaban 60 mg
Number of subjects: 0
Study: 25316860

Group type: EXPERIMENTAL
Intervention: tOPV with sodium bicarbonate and sodium citrate buffer
Number of subjects: 0

Group type: COMPARATOR
Intervention: tOPV without buffer (control)
Number of subjects: 0
Study: 27536427

Group type: EXPERIMENTAL
Intervention: MLK 10mg (7-day administration)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: MLK 10mg (3-day administration)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: MLK 10mg (1-day administration)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study: 19822605

Group type: EXPERIMENTAL
Intervention: Mild hypothermia (32 degrees C)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Moderate hypothermia (25 degrees C)
Number of subjects: 30
Study: 17506738

Group type: EXPERIMENTAL
Intervention: LMA Classic
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Intubating laryngeal mask
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Berman airway
Number of subjects: 72

Group type: COMPARATOR
Intervention: Senior House Officers
Number of subjects: 72

Group type: COMPARATOR
Intervention: All grades of anaesthetists
Number of subjects: 72
Study: 17599422

Group type: EXPERIMENTAL
Intervention: Therapeutic strategy targeting HbA1c level of <6.0%
Number of subjects: 10251

Group type: EXPERIMENTAL
Intervention: Fenofibrate
Number of subjects: 10251

Group type: EXPERIMENTAL
Intervention: Statin plus fenofibrate
Number of subjects: 10251

Group type: EXPERIMENTAL
Intervention: Therapeutic strategy targeting systolic blood pressure of <120 mm Hg
Number of subjects: 10251

Group type: COMPARATOR
Intervention: Statin plus placebo
Number of subjects: 10251

Group type: COMPARATOR
Intervention: Therapeutic strategy targeting systolic blood pressure of <140 mm Hg
Number of subjects: 10251
Study: 12925048

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ) 12.5 mg od
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Indapamide 2.5 mg od
Number of subjects: 18
Study: 10843301

Group type: EXPERIMENTAL
Intervention: Alcohol (dose sufficient to raise blood alcohol level to .08)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Placebo (believed to have consumed alcohol but had not)
Number of subjects: 59

Group type: COMPARATOR
Intervention: No alcohol (neither expected nor received alcohol)
Number of subjects: 59
Study: 9377894

Group type: EXPERIMENTAL
Intervention: Heated humidifier
Number of subjects: 40

Group type: COMPARATOR
Intervention: Heat and moisture exchanger
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Passive airway humidification by a heat and moisture exchanger
Number of subjects: 40
Study: 8076052

Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy
Number of subjects: 2

Group type: COMPARATOR
Intervention: Conventional medical therapy
Number of subjects: 2

Group type: COMPARATOR
Intervention: Conventional non-operative treatment
Number of subjects: 2
Study: 3987178

Group type: COMPARATOR
Intervention: Cimetidine (300 mg every 6 hours by mouth)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Ranitidine (160 mg every 12 hours by mouth)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo (2 days)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Untreated state (O)
Number of subjects: 6